All sponsors

Beijing Mabworks Biotech Co., Ltd.

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS7
PHASE 3 / 2-32
RECRUITING4
READOUTS ≤12 MONTHS0
Open Beijing Mabworks Biotech Co., Ltd. on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
Recombinant Humanized Monoclonal Antibody MIL62 Injection
NCT07044115
P1/2Active, not recruitingLupus Nephritis412025-01-16
MIL62
NCT05314010
P3Active, not recruitingNeuromyelitis Optica Spectrum Disorder1022025-02-21
MBS303
NCT05806099
P1/2RecruitingNon-Hodgkin's Lymphoma1322025-11
MBS314 Injection
NCT06232096
P1/2RecruitingRelapsed or Refractory Multiple Myeloma1542026-02
MBS314 for Injection
NCT07911748
P1/2Not yet recruitingMultiple Myeloma782027-12
MIL116
NCT07375758
P1/2RecruitingImmunoglobulin A Nephropathy1302028-06
MIL62
NCT07405970
P3RecruitingSystemic Lupus Erythematosus3162028-12